These findings highlight the crucial role of LCN2 in regulating VEGF-mediated angiogenesis and promoting tumor lymphangiogenesis through the induction of VEGFC-VEGFR3 interaction, emphasizing its potential as a therapeutic target in breast cancer. This evidence concerns the gene LCN2 and breast cancer.